The effect of the C5a and C5aR1 targeting compounds Vilobelimab (IFX-1) and Avacopan (CCX168) demonstrate the relevance of the inflammatory axis of complement in glomerular diseases. This evidence concerns the gene C5AR1 and glomerular disorder.